Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) was the recipient of a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 5,123,769 shares, an increase of 100.8% from the April 15th total of 2,551,164 shares. Based on an average trading volume of 8 shares, the short-interest ratio is presently 640,471.1 days.
Idorsia Price Performance
Idorsia stock remained flat at $5.75 during midday trading on Friday. Idorsia has a 52-week low of $1.68 and a 52-week high of $5.82. The company has a 50 day simple moving average of $4.27 and a 200 day simple moving average of $4.50.
About Idorsia
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
Read More
- Five stocks we like better than Idorsia
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
